EGFR and neoplasm: Patients with EGFR-amplified tumours (ddPCR CNV score ≥2) also had a lower median OS of 9.74 months (95% CI 3.68 to 11.35 months), compared with 11.18 months for patients with EGFR non-amplified tumours (95% CI 8.78 to 13.16 months) (HR 1.28 (95% CI 0.77 to 2.13); p=0.35).